1. The Field of the Invention
The present disclosure relates to tissue closure apparatuses and methods.
2. The Relevant Technology
During intravascular and other related procedures, catheters are typically inserted through an incision or puncture in the skin and underlying tissues to access an artery or vein, typically in the groin, neck, or subclavian areas of a patient. The catheter can be inserted through a puncture in the blood vessel and guided to the desired site to perform interventional procedures such as angiography, angioplasty, stent delivery, plaque removal, and infusion of a therapeutic substance. After the procedure is completed and the catheter is removed from the patient, however, the access hole must be closed to prevent massive hemorrhage. This is typically achieved by applying pressure over the blood vessel manually and then by applying a pressure bandage or a compressive weight. With conventional methods, the rate of post-puncture hemorrhage is high, which can cause considerable complications. This complication is exacerbated by the concomitant use of anticoagulant medications such as heparin or warfarin and by anti-platelet drugs, which are commonly used following a procedure in order to prevent clot formation and thrombus and/or to treat vascular disease.
It is generally recognized that many currently employed vascular sealing methods and devices and other tissue closure methods and devices have an inherent failure rate due to incomplete sealing of holes or wounds in vascular or other tissue. Achieving complete wound closure is particularly important in sealing arterial punctures, which are relatively high pressure systems. For example, under normal blood pressure, the arterial system has a pressure of about 120/80 mmHg or more. Failure to completely close arterial holes can result in hematoma, exsanguination, and other catastrophic consequences, including limb amputation and death. Moreover, many currently employed vascular devices employ methods and materials that remain on the intravascular endothelial surface or otherwise in the sealed vessel. Materials that remain intravascularly can be a nidus for thrombus or intravascular mural hyperplasia with later spontaneous and catastrophic closure of the vessel.
The present disclosure provides methods and apparatuses that are suitable for closure of vascular punctures or other openings in bodily tissues. The apparatuses and methods disclosed herein provide a redundancy of closure, which enhances wound healing and patient safety. The devices and methods described herein are configured for wound closure on the external surface of the wound, which allows wound healing with little endothelial disruption thereby reducing the chances of intravascular thrombosis or embolism or intimal hyperplasia.
The present disclosure describes a closure device for closing an opening in a tissue. An exemplary tissue closure device according to the present disclosure includes at least one tubular member, a tissue eversion apparatus configured to form an everted tissue region around the opening in the tissue, a first closure element, which can be deployed over the tissue opening around the portion of everted tissue, and a second, redundant closure element that is applied in addition to the first closure element to ensure efficient closure. Combining a first closure and a second, redundant closure provides for wound closure with a failure rate and/or complication rate lower than either acting alone. The devices described herein can be supplied in different diameters (e.g., French sizes) to accommodate different sizes of catheters and different sizes of puncture holes.
The tissue eversion apparatus, the first closure element, and the second closure element are typically disposed in a lumen of one or more tubular members and deployable therefrom. The tubular members can be sheaths having various shapes and/or be formed from various materials, as examples a solid walled or porous walled cylinder or other shape, or a plurality of guide rods or bars mounted relative to each other.
The present disclosure also describes methods for closing an opening in a tissue using, for example, an embodiment of an apparatus as described above. Tissue openings can include openings in a body lumen such as an opening in a blood vessel. An exemplary method for closing an opening in a tissue includes (a) deploying a tissue eversion apparatus into the opening in the body lumen, the tissue eversion apparatus having a plurality of elongate tissue engaging members capable of approximating and everting edges of the opening to form an everted tissue region, (b) deploying a first closure element in a first configuration to the everted tissue region around the opening in the body lumen, (c) transitioning the first closure element that was disposed around the portion of everted tissue to a second, smaller configuration so as to close the opening in the body lumen, (d) retracting the tissue eversion apparatus so as to release the everted edges, and (e) deploying a second closure element over or around the first closure element so as to redundantly close the opening in the body lumen.
According to the present disclosure, the act of deploying a second closure element over or around the first closure element can be performed either before or after retracting the tissue eversion apparatus so as to release the everted edges.
According to the present disclosure, the first closure element can include a cincture element having a first size and a second size that is smaller than the first size. Accordingly, the first size is configured to surround a portion of the everted tissue region around the opening and the second size is configured to capture a portion of the everted tissue region and close the opening when the cincture element is transitioned from the first size towards and/or to the second size.
In one embodiment, the cincture element includes a loop of suture having at least one pre-tied knot, such that the loop can be tightened by pulling on a free-end so as to close the loop and close the tissue opening. In one embodiment, the pre-tied knot can be, for example, a slip knot. In one embodiment, the loop of suture can include at least one dentate configured to maintain the cincture element in a closed position. That is, the at least one dentate can permit the loop to be pulled closed while simultaneously functioning to prevent re-opening of the loop.
In one embodiment, the cincture element can be formed from a shape memory material having an expanded delivery configuration and a contracted deployed configuration. For instance, the shape memory cincture element can be a ring-like structure formed from a metallic material (e.g., NiTi) or a polymeric material (e.g., a rubber-like material) that resiliently closes the opening when the first closure element is deployed around the everted tissue region. The shape memory cincture element may be biased towards the contracted deployed configuration.
Suitable examples of second closure elements that can be applied to the wound after the first closure element is placed can include, but are not limited to, sealant plugs, adhesive glues, occlusive substances, extraluminal clips, RF energy, thermal energy, electrical induction, infrared light, ultrasonic vibration, microwave or laser irradiation, sutures, and combinations thereof.
These and other objects and features of the present disclosure will become more fully apparent from the following description and appended claims, or may be learned by the practice of the invention as set forth hereinafter.
To further clarify the above and other advantages and features of the present disclosure, a more particular description of the invention will be rendered by reference to specific embodiments thereof which are illustrated in the appended drawings. It is appreciated that these drawings depict only illustrated embodiments of the invention and are therefore not to be considered limiting of its scope. The invention will be described and explained with additional specificity and detail through the use of the accompanying drawings in which:
The present disclosure provides apparatuses and methods for closing a vascular puncture wound or any tissue aperture, for example those resulting from the insertion of a vascular catheter or surgical instrument, trauma or disease. The apparatuses and methods disclosed herein provide a redundancy of closure, which enhances wound healing and patient safety. The devices and methods described herein are configured for wound closure on the external surface of the wound, which allows wound healing with little endothelial disruption and thereby reducing the chances of intravascular thrombosis or embolism or intimal hyperplasia.
The description included herein refers to “vessels” for convenience; the present disclosure is applicable to facilitate closure of various types of tissue openings.
The present disclosure describes a closure device for closing an opening in a tissue. An exemplary tissue closure device according to the present disclosure includes at least one tubular member, a tissue eversion apparatus configured to form an everted tissue region around the opening in the tissue, a first closure element, which can be deployed over the tissue opening around the portion of everted tissue, and a second, redundant closure element that is applied in addition to the first closure element to ensure efficient closure.
Referring now to
In another embodiment, the tissue engaging members can be formed from a deformable material, such that the tissue engaging members can bent for disposal in the delivery sheath. For example, the tissue engaging members can include a sharp bend that directs the distal ends of the tissue engaging members toward the proximal end of the delivery sheath. When the tissue engaging members are deployed out of the delivery sheath, the pre-bent shape allows the tissue engaging members to engage with the vessel walls. In yet another embodiment, the tissue engaging members can include hinged members near the distal ends of the engaging members. The hinges can be configured to allow the tissue engaging members to be folded for disposal in the delivery sheath and the hinges can be configured to allow the distal ends of the engaging members to splay out and engage with the vessel walls when the engaging members are deployed into the vessel lumen.
The tissue eversion apparatus 100 shown in
In the embodiments illustrated herein the plurality of tissue engaging members are shown as separate elongate members. One will appreciate, however, that the plurality of members can be coupled together at a point proximal to the distal ends of each of the individual tissue engaging members. For example, the plurality of members can be coupled to an elongate columnar member that can allow the tissue engaging members to be deployed and retracted. Coupling the tissue engaging members proximal to their ends can also be advantageous in that it can reduce the diameter of the tissue region everted by the engaging members in a manner similar to what is shown in
Additional discussion of tissue eversion apparatuses that can be adapted for use in the devices and methods discussed herein can be found in U.S. patent application Ser. No. 11/316,775, filed 23 Dec. 2005, now abandoned, entitled “VASCULAR CLOSURE METHODS AND APPARATUSES” and U.S. patent application Ser. No. 11/508,662, filed 23 Aug. 2006, entitled “VASCULAR OPENING EDGE EVERSION METHODS AND APPARATUSES,” the entireties of which are incorporated herein by reference.
Referring to
The cincture 304a can be attached to a retractable suture loop 310, which is contained in a lumen 308, shown in the Figure as a cylindrical structure. The lumen 308 can include a narrowed portion 312 that permits the cincture material to pass, but prevents a tightening feature (e.g., a functional slipknot) from passing. Thus when the suture loop 310 is pulled, the cincture 304a is reduced in diameter and transitioned towards and/or to the smaller diameter 304b. When the suture loop 310 is pulled in its entirety, the cincture loop 304b completely closes, effecting closure around a portion of everted tissue around an opening (e.g., a puncture wound).
The delivery sheath 402 delivers a cincture 404a, which can be held in place on the sheath 402 by a retention structure 406. The retention structure 406 can prevent the cincture 404a from malpositioning and/or from prematurely contracting. In some embodiments, the retention structure 406 can be slidably positioned on the sheath 402, such that the retention structure 406 can be slid distally on the sheath 402 to act as an actuator to slide the cincture 404a off the sheath 402. The cincture 404a, which can be held by the retention structure 406, can be sufficiently rigid to not readily change position and/or can be temporarily held in place by a wax-like or other semi-solid biocompatible material that will give way, allowing the cincture 404a to slide off the sheath 402 and contract.
The cincture 404a can be attached to a retractable suture loop 410, which is contained in a lumen 408, shown in the Figure as a cylindrical structure. The lumen 408 can comprise a narrowed portion 412 that permits the cincture material to pass, but prevents a tightening feature (e.g., a functional slipknot) from passing. Thus when the suture loop 410 is pulled, the cincture 404a is reduced in diameter and transitioned to the smaller diameter 404b. When the suture loop 410 is pulled in its entirety, the cincture loop 404b completely closes, effecting closure around a portion of everted tissue around an opening (e.g., a puncture wound).
The delivery sheath 502 delivers a cincture 504a, which can be held in place on the sheath 502 by a retention structure 506. The retention structure 506 can prevent the cincture 504a from malpositioning and/or from prematurely contracting. In some embodiments, the retention structure 506 can be slidably positioned on the sheath 502, such that the retention structure 506 can be slid distally on the sheath 502 to act as an actuator to slide the cincture 504a off the sheath 502. The cincture 504a, which can be held by the retention structure 506, can be sufficiently rigid to not readily change position and/or can be temporarily held in place by a wax-like or other semi-solid biocompatible material that will give way, allowing the cincture 504a to slide off the sheath 502 and contract.
The cincture 504a can be attached to a retractable suture loop 510, which is contained in a lumen 508, shown in the Figure as a cylindrical structure. The retractable suture loop 510 can be used to pull the cincture 504a past the end of the sheath 502. If the retention structure 506 is slidably disposed on the sheath 502, or otherwise has the ability to move the cincture past the end of the sheath 502, then the suture loop 510 may not be might not be necessary (although it can still be useful for retrieving misplaced cinctures). When the self contracting cincture 504a is moved past the end of the sheath 502, by action of the suture loop 510 or the retention device 506, the cincture contracts adopting configuration 504b, reducing its radius, effecting closure around a portion of everted tissue around an opening (e.g., a puncture wound).
As shown in
As shown, the elongate tissue engaging members 604b pierce a portion of the everted tissue region 606a. Nonetheless, one will appreciate that the tissue engaging members 604b need not pierce the tissue in order to engage the tissue to form the everted tissue region 606a. For example, any known gripping means such as apposing feet, hooks, teeth, adhesive devices and the like can be used to engage the tissue around the opening to form the everted tissue region.
Referring now to
After the cincture 612b is placed, the second sheath 610 can be removed, leaving the opening closed by the cincture 612b, as shown in
Additional discussion of cincture apparatuses that can be adapted for use with the devices and methods discussed herein can be found in U.S. patent application Ser. No. 11/508,715, filed 23 Aug. 2006, entitled “VASCULAR CLOSURE METHODS AND APPARATUSES,” the entirety of which is incorporated herein by reference.
The clip 1102 shown in
Additional discussion of clip apparatuses that can be adapted for use with the devices and methods discussed herein can be found in U.S. patent application Ser. No. 11/508,656, filed 23 Aug. 2006, entitled “VASCULAR CLOSURE METHODS AND APPARATUSES,” the entirety of which is incorporated herein by reference.
Additional examples of second, redundant closure elements that can be applied to or around the wound after placing the first closure element can include, but are not limited to, RF energy, thermal energy, electrical induction, infrared light, ultrasonic vibration, microwave or laser irradiation, sutures, and combinations thereof. For example, heat (i.e., thermal energy) can be applied to the wound region after applying the first closure element to cauterize the wound and provide redundant closure.
The embodiments shown in the Figures presented herein show the tissue eversion apparatus and the first and second closure elements being delivered by separate elongate members (i.e., sheaths). One will appreciate, however, that the figures are presented for illustrative purposes and that the tissue eversion apparatus and the first and second closure elements can be delivered by a single elongate member.
Examples of knots that can be suitable for use with the present disclosure include, but are not limited to, the overhand knot or half knot, the double overhand knot, the multifold-overhand-knot, the Flemish eight, hitches (single simple, half, clove, two half, buntline, rolling Magnus, midshipman's tautline, adjustable jamming, cow, reversed half, lobster buoy), single loops (bowline, Dutch marine bowline, cowboy bowline, double figure-of-eight loop, Flemish eight, bowstring knot, tucked double overhand, butterfly loop, lineman's loop, artillery loop, pendant hitch), clove hitch, reef knot, square knot, noose (simple noose, strangle-snare, scaffold knot, gallows knot, hangman's knot, reverse eight-noose), monkey fist, the dolly, fisherman's bend, surgeon's knot, sheet bend knot, timber hitch, fisherman's knot, reef knot, square knot, DuraKnot, sliding knots, simple sliding knot, Nicky's knot, Roeder's knot, Seoul Medical Centre knot, Smith & Nephew's knot, Tennesee's knot, purse string, surgical knot with extra loop, other knots and/or cincture devices or combinations thereof could also be used and are anticipated. Endoscopic knot tying devices and suture cutting devices can also be used to create the cincture for this device and are also anticipated.
Examples of suture material at can be suitable for use with the present disclosure include, but are not limited to, absorbable, non-absorbable, braided, monofilament, pseudo-monofilament, multifilament, barbed, smooth, directional, and bidirectional. The suture material can be composed of but not limited to polyglycolic acid, polydioxanon, polylactate, polycaprone, silk, linen, cotton, treated and non-treated collagen, “catgut”, chromic, Vicryl, Monocyrl, PDS, polyesther, poypropylene, polyamide, stainless steel, and others. The cincture device can be made from other suitable materials, including typical suture materials, flexible polymeric materials with elastomeric properties including polyurethane, polyethylene, polyestenurethane, polyimide, olyethreimide, polycarbonate, polysiloxane, polyvinyls, hydroxyethylmethacrylate, related polymers, co-polymers of these or other polymers, or drug-embedded or drug-eluting polymers to prevent coagulation or intimal hyperplasia (such as Taxol), also which can be made radiopaque by markers and addition of appropriate radiopaque materials.
The tines or gripping portion of a the tissue engaging members or components of the sheath or cincture device can be made from any number of suitable materials, including radiopaque materials and materials coated to be made radiopaque, including bioabsorbable polymers or compounds, non-absorbable alloys and compounds including stainless steel, MP35, Nitinol, Nickel-Titanium alloy, Kevlar, nylon polyester acrylic, gold, platinum, tantalum, niobium, molybdenum, rhodium, palladium silver, hafnium, tungsten, iridium. Materials with memory can be useful to allow tines to spontaneously open after extended from the sheath. These can be made in the form of wires, fibers, filaments, small beams, and other extruded, woven, or formed shapes. Piano wire, super elastic memory wire, chromium allows, alloys of titanium and nickel, and other elastic memory materials previously mentioned as well as others can be used as well.
The sealant plug, injected sealant, and injected occlusive material can be composed of an appropriate biocompatible materials including but not limited to fibrin and cross-linked fibrin autologous blood clot formed by blood mixed with topical thrombin, the above clot treated with epsilon-aminocaproic acid providing a more stable clot and delaying lysis; Gelfoam, Ivalon, Oxycel and other particulate materials, biocompatible polymer including an alginate, chitosan and poly-L-amino acid, sodium alginate, potassium alginate, strontium alginate, barium alginate, magnesium alginate or any other alginate or a mixture thereof; poly-L-lysine, poly-L-arginine, poly-L-glutamic acid, poly-L-histidine, poly-a-D-glutamic acid or a mixture thereof; platelet-rich plasma and a biocompatible polymer; mixture of fibrin and fibrinogen; fibrin microbeads, collagen, cross-linked collagen and other collagen-derivatives, polysaccharides, cellulosics, polymers (natural and synthetic), inorganic oxides, ceramics, zeolites, glasses, metals, and composites; dextran beads; microporous polysaccharide beads; tackified natural rubbers; synthetic rubbers such as butyl rubber; and tackified linear, radial, star, and branched and tapered styrene block copolymers, such as styrene-butadiene, styrene-ethylene/butylene and styrene-isoprene; polyurethanes; polyvinyl ethers; acrylics, especially those having long chain alkyl groups; poly-a-olefins; and silicones; a platelet glue (platelets-fibrinogen-fibrinogen activator) wound sealant; pressure glues, polymer glues, polyglycolic acid, polydioxanon, polylactate, polycaprone; flexible polymeric materials with elastomeric properties including polyurethane, polyethylene, polyestenurethane, polyimide, olyethreimide, polycarbonate, polysiloxane, polyvinyls, hydroxyethylmethacrylate, related polymers, co-polymers of these or other polymers, or drug-embedded or drug-eluting polymers to prevent coagulation or intimal hyperplasia (such as Taxol), also which can be made radiopaque by markers and addition of appropriate radiopaque materials.
The extraluminal clip and/or hemostatic wafer clip could be constructed of any of the above absorbable or non-absorbable materials but also any number of suitable materials, including radiopaque materials and materials coated to be made radiopaque, including bioabsorbable polymers or compounds, non-absorbable alloys and compounds including stainless steel, MP35, Nitinol, Nickel-Titanium alloy, Kevlar, nylon polyester acrylic, gold, platinum, tantalum, niobium, molybdenum, rhodium, palladium silver, hafnium, tungsten, iridium.
The present disclosure may be embodied in other specific forms without departing from its spirit or essential characteristics. The described embodiments are to be considered in all respects only as illustrative and not restrictive. The scope of the invention is, therefore, indicated by the appended claims rather than by the foregoing description. All changes which come within the meaning and range of equivalency of the claims are to be embraced within their scope.
This application claims the benefit of and priority to U.S. Provisional Pat. App. No. 61/097,072, filed 15 Sep. 2008, entitled “REDUNDANT TISSUE CLOSURE METHODS AND APPARATUSES.” This application is a continuation of U.S. patent application Ser. No. 12/365,397, filed 4 Feb. 2009, now U.S. Pat. No. 8,048,108, entitled “VASCULAR CLOSURE METHODS AND APPARATUSES,” which is a continuation of U.S. patent application Ser. No. 11/316,775, filed 23 Dec. 2005, entitled “VASCULAR CLOSURE METHODS AND APPARATUSES,” now abandoned, which claims the benefit of and priority to U.S. Provisional App. No. 60/711,279, filed 24 Aug. 2005, entitled “VASCULAR CLOSURE METHODS AND APPARATUSES.” This application is a continuation-in-part of U.S. patent application Ser. No. 11/508,656, filed 23 Aug. 2006, entitled “VASCULAR CLOSURE METHODS AND APPARATUSES,” which claims the benefit of and priority to U.S. Provisional Pat. App. No. 60/711,279, filed 24 Aug. 2005, entitled “VASCULAR CLOSURE METHODS AND APPARATUSES,” and which is a continuation-in-part of U.S. patent application Ser. No. 11/316,775, filed 23 Dec. 2005, entitled, “VASCULAR CLOSURE METHODS AND APPARATUSES,” now abandoned, which claims the benefit of and priority to U.S. Provisional Pat. App. No. 60/711,279, filed 24 Aug. 2005, entitled “VASCULAR CLOSURE METHODS AND APPARATUSES.” This application is a continuation-in-part of U.S. patent application Ser. No. 11/508,715, filed 23 Aug. 2006, entitled “VASCULAR CLOSURE METHODS AND APPARATUSES,” which claims the benefit of and priority to U.S. Provisional Pat. App. No. 60/711,279, filed 24 Aug. 2005, entitled “VASCULAR CLOSURE METHODS AND APPARATUSES,” and which is a continuation-in-part of U.S. patent application Ser. No. 11/316,775, filed 23 Dec. 2005, entitled, “VASCULAR CLOSURE METHODS AND APPARATUSES,” now abandoned, which claims the benefit of and priority to U.S. Provisional Pat. App. No. 60/711,279, filed 24 Aug. 2005, entitled “VASCULAR CLOSURE METHODS AND APPARATUSES.” This application is a continuation-in-part of U.S. patent application Ser. No. 11/508,662, filed 23 Aug. 2006, entitled “VASCULAR OPENING EDGE EVERSION METHODS AND APPARATUSES,” which claims the benefit of and priority to U.S. Provisional Pat. App. No. 60/711,279, filed 24 Aug. 2005, entitled “VASCULAR CLOSURE METHODS AND APPARATUSES,” and claims benefit of and priority to U.S. Provisional Pat. App. No. 60/726,985, filed 14 Oct. 2005, entitled “SEALANT PLUG SYRINGES, TUBES, AND PENCILS,” and which is a continuation-in-part of U.S. patent application Ser. No. 11/316,775, filed 23 Dec. 2005, entitled, “VASCULAR CLOSURE METHODS AND APPARATUSES,” now abandoned, which claims the benefit of and priority to U.S. Provisional Pat. App. No. 60/711,279, filed 24 Aug. 2005, entitled “VASCULAR CLOSURE METHODS AND APPARATUSES.” The entire disclosures of each of the above are hereby incorporated by reference in their entirety.
Number | Name | Date | Kind |
---|---|---|---|
1242139 | Callahan | Oct 1917 | A |
1480935 | Gleason | Jan 1924 | A |
2108206 | Meeker | Feb 1938 | A |
2371978 | Perham | Mar 1945 | A |
2610631 | Calicchio | Sep 1952 | A |
3348595 | Stevens, Jr. | Oct 1967 | A |
3357070 | Sloan | Dec 1967 | A |
3682180 | McFarlane | Aug 1972 | A |
3814104 | Irnich et al. | Jun 1974 | A |
3856018 | Perisse et al. | Dec 1974 | A |
3874388 | King et al. | Apr 1975 | A |
3908662 | Razgulov et al. | Sep 1975 | A |
3926194 | Greenberg et al. | Dec 1975 | A |
3939820 | Grayzel | Feb 1976 | A |
3985138 | Jarvik | Oct 1976 | A |
4011872 | Komiya | Mar 1977 | A |
4018228 | Goosen | Apr 1977 | A |
4018229 | Komiya | Apr 1977 | A |
4189808 | Brown | Feb 1980 | A |
4267995 | McMillan | May 1981 | A |
4501276 | Lombardi | Feb 1985 | A |
4697312 | Freyer | Oct 1987 | A |
4830002 | Semm | May 1989 | A |
5041129 | Hayhurst et al. | Aug 1991 | A |
5059201 | Asnis | Oct 1991 | A |
5100422 | Berguer et al. | Mar 1992 | A |
5176691 | Pierce | Jan 1993 | A |
5192287 | Fournier et al. | Mar 1993 | A |
5217471 | Burkhart | Jun 1993 | A |
5237996 | Waldman et al. | Aug 1993 | A |
5254105 | Haaga | Oct 1993 | A |
5290284 | Adair | Mar 1994 | A |
5300078 | Buelna | Apr 1994 | A |
5330445 | Haaga | Jul 1994 | A |
5336231 | Adair | Aug 1994 | A |
5354279 | Hofling | Oct 1994 | A |
5383905 | Golds et al. | Jan 1995 | A |
5403330 | Tuason | Apr 1995 | A |
5403331 | Chesterfield et al. | Apr 1995 | A |
5404621 | Heinke | Apr 1995 | A |
5425740 | Hutchinson, Jr. | Jun 1995 | A |
5462561 | Voda | Oct 1995 | A |
5466241 | Leroy et al. | Nov 1995 | A |
5478353 | Yoon | Dec 1995 | A |
5478354 | Tovey et al. | Dec 1995 | A |
5486186 | Yoon | Jan 1996 | A |
5489288 | Buelna | Feb 1996 | A |
5492119 | Abrams | Feb 1996 | A |
5507744 | Tay et al. | Apr 1996 | A |
5536267 | Edwards et al. | Jul 1996 | A |
5562684 | Kammerer | Oct 1996 | A |
5571120 | Yoon | Nov 1996 | A |
5573540 | Yoon | Nov 1996 | A |
5609597 | Lehrer | Mar 1997 | A |
5613974 | Andreas et al. | Mar 1997 | A |
5613975 | Christy | Mar 1997 | A |
5643318 | Tsukernik et al. | Jul 1997 | A |
5647372 | Tovey et al. | Jul 1997 | A |
5649959 | Hannam et al. | Jul 1997 | A |
5669935 | Rosenman et al. | Sep 1997 | A |
5672174 | Gough et al. | Sep 1997 | A |
5674231 | Green et al. | Oct 1997 | A |
5693061 | Pierce et al. | Dec 1997 | A |
5713899 | Marnay et al. | Feb 1998 | A |
5728143 | Gough et al. | Mar 1998 | A |
5735736 | Volk | Apr 1998 | A |
5749898 | Schulze et al. | May 1998 | A |
5759189 | Ferragamo et al. | Jun 1998 | A |
5766217 | Christy | Jun 1998 | A |
5782861 | Cragg et al. | Jul 1998 | A |
5792151 | Heck et al. | Aug 1998 | A |
5797928 | Kogasaka | Aug 1998 | A |
5797929 | Andreas et al. | Aug 1998 | A |
5810845 | Yoon | Sep 1998 | A |
5814052 | Nakao et al. | Sep 1998 | A |
5817113 | Gifford, III et al. | Oct 1998 | A |
5845657 | Carberry et al. | Dec 1998 | A |
5855576 | LeVeen et al. | Jan 1999 | A |
5861005 | Kontos | Jan 1999 | A |
5865791 | Whayne et al. | Feb 1999 | A |
5873876 | Christy | Feb 1999 | A |
5897487 | Ouchi | Apr 1999 | A |
5906620 | Nakao et al. | May 1999 | A |
5906631 | Imran | May 1999 | A |
5919207 | Taheri | Jul 1999 | A |
5944728 | Bates | Aug 1999 | A |
5951547 | Gough et al. | Sep 1999 | A |
5957936 | Yoon et al. | Sep 1999 | A |
5957938 | Zhu et al. | Sep 1999 | A |
5964782 | Lafontaine et al. | Oct 1999 | A |
5972009 | Fortier et al. | Oct 1999 | A |
5976161 | Kirsch et al. | Nov 1999 | A |
5980517 | Gough et al. | Nov 1999 | A |
5984950 | Cragg et al. | Nov 1999 | A |
5993466 | Yoon | Nov 1999 | A |
5993476 | Groiso | Nov 1999 | A |
6009877 | Edwards | Jan 2000 | A |
6022372 | Kontos | Feb 2000 | A |
6024747 | Kontos | Feb 2000 | A |
6056744 | Edwards | May 2000 | A |
6059719 | Yamamoto et al. | May 2000 | A |
6068603 | Suzuki | May 2000 | A |
6083242 | Cook | Jul 2000 | A |
6095155 | Criscuolo | Aug 2000 | A |
6120513 | Bailey et al. | Sep 2000 | A |
6120524 | Taheri | Sep 2000 | A |
6126675 | Shchervinsky et al. | Oct 2000 | A |
6136010 | Modesitt et al. | Oct 2000 | A |
6143004 | Davis et al. | Nov 2000 | A |
6152936 | Christy et al. | Nov 2000 | A |
6161263 | Anderson | Dec 2000 | A |
6165204 | Levinson et al. | Dec 2000 | A |
6178355 | Williams et al. | Jan 2001 | B1 |
6197042 | Ginn et al. | Mar 2001 | B1 |
6221084 | Fleenor | Apr 2001 | B1 |
6248124 | Pedros et al. | Jun 2001 | B1 |
6296657 | Brucker | Oct 2001 | B1 |
6306081 | Ishikawa et al. | Oct 2001 | B1 |
6322580 | Kanner | Nov 2001 | B1 |
6358258 | Arcia et al. | Mar 2002 | B1 |
6395015 | Borst et al. | May 2002 | B1 |
6397110 | Kuzma | May 2002 | B1 |
6428472 | Haas | Aug 2002 | B1 |
6443963 | Baldwin et al. | Sep 2002 | B1 |
6461366 | Seguin | Oct 2002 | B1 |
6482224 | Michler et al. | Nov 2002 | B1 |
6506209 | Ouchi | Jan 2003 | B2 |
6517498 | Burbank et al. | Feb 2003 | B1 |
6533812 | Swanson et al. | Mar 2003 | B2 |
6547806 | Ding | Apr 2003 | B1 |
6569159 | Edwards et al. | May 2003 | B1 |
6569185 | Ungs | May 2003 | B2 |
6572629 | Kalloo et al. | Jun 2003 | B2 |
6578585 | Stachowski et al. | Jun 2003 | B1 |
6599311 | Biggs et al. | Jul 2003 | B1 |
6610072 | Christy et al. | Aug 2003 | B1 |
6613060 | Adams et al. | Sep 2003 | B2 |
6623509 | Ginn | Sep 2003 | B2 |
6623510 | Carley et al. | Sep 2003 | B2 |
6663655 | Ginn et al. | Dec 2003 | B2 |
6676685 | Pedros et al. | Jan 2004 | B2 |
6679904 | Gleeson et al. | Jan 2004 | B2 |
6689051 | Nakada et al. | Feb 2004 | B2 |
6695867 | Ginn et al. | Feb 2004 | B2 |
6736822 | McClellan et al. | May 2004 | B2 |
6743195 | Zucker | Jun 2004 | B2 |
6743259 | Ginn | Jun 2004 | B2 |
6745079 | King | Jun 2004 | B2 |
6746457 | Dana et al. | Jun 2004 | B2 |
6749621 | Pantages et al. | Jun 2004 | B2 |
6749622 | McGuckin, Jr. et al. | Jun 2004 | B2 |
6767356 | Kanner et al. | Jul 2004 | B2 |
6776785 | Yencho et al. | Aug 2004 | B1 |
6837906 | Ginn | Jan 2005 | B2 |
6846319 | Ginn et al. | Jan 2005 | B2 |
6849078 | Durgin et al. | Feb 2005 | B2 |
6890343 | Ginn et al. | May 2005 | B2 |
6896692 | Ginn et al. | May 2005 | B2 |
6904647 | Byers, Jr. | Jun 2005 | B2 |
6942674 | Belef et al. | Sep 2005 | B2 |
6969397 | Ginn | Nov 2005 | B2 |
6984238 | Gifford, III et al. | Jan 2006 | B2 |
7048747 | Arcia et al. | May 2006 | B2 |
7060084 | Lashakove et al. | Jun 2006 | B1 |
7063661 | Okada | Jun 2006 | B2 |
7063711 | Loshakove et al. | Jun 2006 | B1 |
7083635 | Ginn | Aug 2006 | B2 |
7112225 | Ginn | Sep 2006 | B2 |
7122002 | Okada | Oct 2006 | B2 |
7147646 | Dana et al. | Dec 2006 | B2 |
7270672 | Singer | Sep 2007 | B1 |
7316704 | Bagaoisan et al. | Jan 2008 | B2 |
7326230 | Ravikumar | Feb 2008 | B2 |
7331979 | Khosravi et al. | Feb 2008 | B2 |
7335220 | Khosravi et al. | Feb 2008 | B2 |
7338514 | Wahr et al. | Mar 2008 | B2 |
7361183 | Ginn | Apr 2008 | B2 |
7361185 | O'Malley et al. | Apr 2008 | B2 |
7393363 | Ginn | Jul 2008 | B2 |
7396359 | Derowe et al. | Jul 2008 | B1 |
7431727 | Cole et al. | Oct 2008 | B2 |
7507200 | Okada | Mar 2009 | B2 |
7645285 | Cosgrove et al. | Jan 2010 | B2 |
7648493 | Forsberg et al. | Jan 2010 | B2 |
7727249 | Rahmani | Jun 2010 | B2 |
7731655 | Smith et al. | Jun 2010 | B2 |
7749249 | Gelbart et al. | Jul 2010 | B2 |
7799042 | Williamson, IV et al. | Sep 2010 | B2 |
7901428 | Ginn et al. | Mar 2011 | B2 |
8226666 | Zarbatany et al. | Jul 2012 | B2 |
8313497 | Walberg et al. | Nov 2012 | B2 |
8469969 | Kear et al. | Jun 2013 | B2 |
8480687 | Ducharme et al. | Jul 2013 | B2 |
20010046518 | Sawhney | Nov 2001 | A1 |
20010053909 | Nakada | Dec 2001 | A1 |
20020099389 | Michler et al. | Jul 2002 | A1 |
20020106409 | Sawhney et al. | Aug 2002 | A1 |
20020188275 | McGuckin, Jr. | Dec 2002 | A1 |
20030187457 | Weber | Oct 2003 | A1 |
20030233095 | Urbanski et al. | Dec 2003 | A1 |
20040009205 | Sawhney | Jan 2004 | A1 |
20040093027 | Fabisiak et al. | May 2004 | A1 |
20040098044 | Van de Moer et al. | May 2004 | A1 |
20040116943 | Brandt et al. | Jun 2004 | A1 |
20040122349 | Lafontaine et al. | Jun 2004 | A1 |
20040127940 | Ginn et al. | Jul 2004 | A1 |
20040143290 | Brightbill | Jul 2004 | A1 |
20040158127 | Okada | Aug 2004 | A1 |
20040158287 | Cragg et al. | Aug 2004 | A1 |
20040167511 | Buehlmann et al. | Aug 2004 | A1 |
20040191277 | Sawhney et al. | Sep 2004 | A1 |
20040215232 | Belhe et al. | Oct 2004 | A1 |
20040225194 | Smith et al. | Nov 2004 | A1 |
20040236354 | Seguin | Nov 2004 | A1 |
20040267193 | Bagaoisan et al. | Dec 2004 | A1 |
20040267308 | Bagaoisan et al. | Dec 2004 | A1 |
20050010248 | Lafontaine | Jan 2005 | A1 |
20050033359 | Dycus | Feb 2005 | A1 |
20050075665 | Brenzel et al. | Apr 2005 | A1 |
20050085851 | Fiehler et al. | Apr 2005 | A1 |
20050085854 | Ginn | Apr 2005 | A1 |
20050085855 | Forsberg | Apr 2005 | A1 |
20050090859 | Ravlkumar | Apr 2005 | A1 |
20050121042 | Belhe et al. | Jun 2005 | A1 |
20050149117 | Khosravi et al. | Jul 2005 | A1 |
20050177189 | Ginn et al. | Aug 2005 | A1 |
20050222614 | Ginn et al. | Oct 2005 | A1 |
20050234396 | Forsberg et al. | Oct 2005 | A1 |
20050245876 | Khosravi et al. | Nov 2005 | A1 |
20050256532 | Nayak et al. | Nov 2005 | A1 |
20050261708 | Pasricha et al. | Nov 2005 | A1 |
20050267528 | Ginn et al. | Dec 2005 | A1 |
20050273137 | Ginn | Dec 2005 | A1 |
20060034930 | Khosravi et al. | Feb 2006 | A1 |
20060047313 | Khanna et al. | Mar 2006 | A1 |
20060058844 | White et al. | Mar 2006 | A1 |
20060089635 | Young et al. | Apr 2006 | A1 |
20060095029 | Young et al. | May 2006 | A1 |
20060100664 | Pai et al. | May 2006 | A1 |
20060106420 | Dolan et al. | May 2006 | A1 |
20060253037 | Ginn et al. | Nov 2006 | A1 |
20060253072 | Pai et al. | Nov 2006 | A1 |
20060259049 | Harada et al. | Nov 2006 | A1 |
20070049967 | Sibbitt, Jr. et al. | Mar 2007 | A1 |
20070049968 | Sibbitt, Jr. et al. | Mar 2007 | A1 |
20070060895 | Sibbitt, Jr. et al. | Mar 2007 | A1 |
20070060950 | Khosravi et al. | Mar 2007 | A1 |
20070060951 | Shannon | Mar 2007 | A1 |
20070083231 | Lee | Apr 2007 | A1 |
20070123817 | Khosravi et al. | May 2007 | A1 |
20070123936 | Goldin et al. | May 2007 | A1 |
20070198058 | Gelbart et al. | Aug 2007 | A1 |
20070203506 | Sibbitt, Jr. et al. | Aug 2007 | A1 |
20070213747 | Monassevitch et al. | Sep 2007 | A1 |
20080009794 | Bagaoisan et al. | Jan 2008 | A1 |
20080045979 | Ma | Feb 2008 | A1 |
20080065151 | Ginn | Mar 2008 | A1 |
20080065152 | Carley | Mar 2008 | A1 |
20080287967 | Andreas et al. | Nov 2008 | A1 |
20080287988 | Smith et al. | Nov 2008 | A1 |
20090088794 | LaFontaine | Apr 2009 | A1 |
20090105728 | Noda et al. | Apr 2009 | A1 |
20090157101 | Reyes et al. | Jun 2009 | A1 |
20090254119 | Sibbitt, Jr. et al. | Oct 2009 | A1 |
20100234884 | Lafontaine et al. | Sep 2010 | A1 |
20110066163 | Cho et al. | Mar 2011 | A1 |
20120245603 | Voss | Sep 2012 | A1 |
20120296374 | Ziobro et al. | Nov 2012 | A1 |
Number | Date | Country |
---|---|---|
2768324 | Mar 1999 | FR |
2000014634 | Jan 2000 | JP |
2005218868 | Aug 2005 | JP |
WO 9640356 | Dec 1996 | WO |
WO 0056226 | Sep 2000 | WO |
WO 02062234 | Aug 2002 | WO |
WO 03094748 | Nov 2003 | WO |
WO 2005000126 | Jan 2005 | WO |
WO 2005041782 | May 2005 | WO |
WO 2005063129 | Jul 2005 | WO |
WO 2005092204 | Oct 2005 | WO |
WO 2005112782 | Dec 2005 | WO |
WO 2006026116 | Mar 2006 | WO |
WO 2006052611 | May 2006 | WO |
WO 2006052612 | May 2006 | WO |
WO 2006078578 | Jul 2006 | WO |
WO 2006115901 | Nov 2006 | WO |
WO 2006115904 | Nov 2006 | WO |
WO 2006118877 | Nov 2006 | WO |
WO 2007025014 | Mar 2007 | WO |
WO 2007025017 | Mar 2007 | WO |
WO 2007025018 | Mar 2007 | WO |
WO 2007025019 | Mar 2007 | WO |
WO 2007081836 | Jul 2007 | WO |
WO 2010031050 | Mar 2010 | WO |
Entry |
---|
U.S. Appl. No. 60/711,279, filed Aug. 24, 2005, Sibbitt, Jr. et al. |
U.S. Appl. No. 60/726,985, filed Oct. 14, 2005, Sibbitt Jr. et al. |
U.S. Appl. No. 61/097,072, filed Sep. 16, 2008, Sibbitt Jr. et al. |
U.S. Appl. No. 11/316,775, Apr. 16, 2008, Office Action. |
U.S. Appl. No. 11/316,775, Aug. 6, 2008, Office Action. |
U.S. Appl. No. 11/508,656, Dec. 9, 2009, Office Action. |
U.S. Appl. No. 11/508,656, Mar. 25, 2010, Office Action. |
U.S. Appl. No. 11/508,656, Aug. 30, 2010, Office Action. |
U.S. Appl. No. 11/508,662, Dec. 28, 2009, Office Action |
U.S. Appl. No. 11/508,662, Apr. 14, 2010, Office Action. |
U.S. Appl. No. 11/508,662, Oct. 26, 2010, Office Action. |
U.S. Appl. No. 11/508,715, Apr. 26, 2010, Office Action. |
U.S. Appl. No. 11/508,715, Jan. 6, 2010, Office Action. |
U.S. Appl. No. 11/508,715, Oct. 18, 2010, Office Action. |
U.S. Appl. No. 12/365,397, Sep. 13, 2010, Office Action. |
U.S. Appl. No. 12/365,397, Dec. 17, 2010, Office Action. |
U.S. Appl. No. 12/365,397, Jun. 21, 2011, Notice of Allowance. |
U.S. Appl. No. 11/508,656, Feb. 10, 2014, Notice of Allowance. |
U.S. Appl. No. 11/508,662, Mar. 24, 2014, Office Action. |
U.S. Appl. No. 11/508,715, Mar. 27, 2014, Office Action. |
U.S. Appl. No. 13/052,634, Feb. 8, 2013, Restriction Requirement. |
U.S. Appl. No. 13/052,634, Apr. 22, 2013, Office Action. |
U.S. Appl. No. 13/052,634, Nov. 8, 2013, Office Action. |
U.S. Appl. No. 13/111,403, Jun. 28, 2013, Restriction Requirement. |
U.S. Appl. No. 13/111,403, Sep. 5, 2013, Office Action. |
U.S. Appl. No. 13/111,403, Dec. 24, 2013, Office Action. |
U.S. Appl. No. 11/508,656, Jun. 4, 2014, Issue Notification. |
U.S. Appl. No. 11/508,662, Jul. 25, 2014, Notice of Allowance. |
Number | Date | Country | |
---|---|---|---|
20100130965 A1 | May 2010 | US |
Number | Date | Country | |
---|---|---|---|
60711279 | Aug 2005 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 12365397 | Feb 2009 | US |
Child | 12559377 | US | |
Parent | 11316775 | Dec 2005 | US |
Child | 12365397 | US | |
Parent | 12559377 | US | |
Child | 12365397 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 11508656 | Aug 2006 | US |
Child | 12559377 | US | |
Parent | 11316775 | US | |
Child | 11508656 | US | |
Parent | 12559377 | US | |
Child | 11508656 | US | |
Parent | 11508715 | Aug 2006 | US |
Child | 12559377 | US | |
Parent | 11318775 | US | |
Child | 11508715 | US | |
Parent | 12559377 | US | |
Child | 11508715 | US | |
Parent | 11508662 | Aug 2006 | US |
Child | 12559377 | US | |
Parent | 11316775 | US | |
Child | 11508662 | US |